Lorenzo Galluzzi is Assistant Professor of Cell Biology in Radiation Oncology at the Department of Radiation Oncology of the Weill Cornell Medical College, Honorary Assistant Professor Adjunct with the Department of Dermatology of the Yale School of Medicine, Honorary Associate Professor with the Faculty of Medicine of the University of Paris, and Faculty Member with the Graduate School of Biomedical Sciences and Biotechnology of the University of Ferrara, the Graduate School of Pharmacological Sciences of the University of Padova, and the Graduate School of Network Oncology and Precision Medicine of the University of Rome “La Sapienza”. Moreover, he is Associate Director of the European Academy for Tumor Immunology and Founding Member of the European Research Institute for Integrated Cellular Pathology. Galluzzi is best known for major experimental and conceptual contributions to the fields of cell death, autophagy, tumor metabolism and tumor immunology. He has published over 450 articles in international peer-reviewed journals and is the Editor-in-Chief of four journals: OncoImmunology (which he co-founded in 2011), International Review of Cell and Molecular Biology, Methods in Cell biology, and Molecular and Cellular Oncology (which he co-founded in 2013). Additionally, he serves as Founding Editor for Microbial Cell and Cell Stress, and Associate Editor for Cell Death and Disease, Pharmacological Research and iScience. Dr. Céline Mirjolet is a radiobiologist with in-depth knowledge of the impact of radiotherapy fractionation on the radiation-induced immune response and on the effectiveness of the radiotherapy and immunotherapy combination. She obtained a doctorate in radiobiology at the anti-cancer center of Nancy (France). She then moved to Brussels at the University of Belgium to study epigenetic mechanisms in transcriptional activity and cancer. For ten years, she has been working in the radiotherapy department of the Dijon cancer center in close collaboration with clinicians and physicists to develop translational research projects on the combination of immunotherapy and radiotherapy. She leads the preclinical research team in radiotherapy and radiobiology and her programs focus on the validation of preclinical concepts leading to the design of clinical trials.